Cantor Fitzgerald & ADMA Biologics

Cantor Fitzgerald: Cantor Fitzgerald downgraded ADMA Biologics' stock, citing disappointment with the company's response to the Culper Research report, further contributing to the stock's decline.

ADMA Biologics: ADMA Biologics is the primary subject of the class action lawsuits and investigations due to allegations of channel stuffing, undisclosed related-party transactions, and misleading revenue growth, which caused its stock price to decline significantly.

Cantor Fitzgerald: Cantor Fitzgerald downgraded ADMA Biologics stock from Overweight to Neutral following the Culper Research report.

ADMA Biologics: ADMA Biologics is the defendant in the securities class action, accused of making false and misleading statements. The lawsuit and allegations have led to a significant drop in its stock price and could result in substantial financial penalties and reputational harm.